GlassScriptPhysician profile
Anvi Gadani
NPI 1083061329
$32,711.58
in general payments reported to CMS, 2019-2025
31 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $4,039 · 2021: $22K · 2022: $1,671 · 2023: $1,368 · 2024: $2,281 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,828 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,827.93 |
| Education | $251.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $21,595.17 | 2021-2024 | Percept PC Brainsense |
| Medtronic USA, INC. | $4,000.00 | 2020 | |
| Abbvie INC. | $1,092.74 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $719.81 | 2022-2025 | Nuplazid |
| Mdd US Operations, LLC | $595.37 | 2021-2025 | Gocovri, Gocovri |
| Teva Pharmaceuticals USA, INC. | $565.90 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lilly USA, LLC | $499.35 | 2023-2025 | Kisunla, Amyvid |
| Kyowa Kirin, INC. | $422.72 | 2021-2024 | Nourianz |
| Eisai INC. | $401.40 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $323.09 | 2022-2025 | Ingrezza, Ongentys |
| Supernus Pharmaceuticals, INC. | $279.95 | 2024 | |
| Acorda Therapeutics, INC | $263.70 | 2021-2024 | Ampyra, Inbrija |
| Amneal Pharmaceuticals LLC | $249.73 | 2022-2025 | Rytary, Ongentys, Lyvispah |
| Adamas Pharmaceuticals, INC. | $204.95 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $199.67 | 2022-2024 | Ultomiris, Soliris |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $195.65 | 2022-2025 | Xeomin, Inbrija |
| Boston Scientific Corporation | $177.82 | 2022-2024 | Vercise |
| Allergan, INC. | $159.60 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $123.25 | 2023-2024 | Rexulti, Nuedexta |
| Biogen, INC. | $113.96 | 2022-2025 | Vumerity, Tysabri, Tecfidera |
| Novartis Pharmaceuticals Corporation | $90.63 | 2023-2024 | |
| Revance Therapeutics, INC. | $81.00 | 2024 | Daxxify |
| Avion Pharmaceuticals | $80.69 | 2022-2023 | Dhivy |
| Ani Pharmaceuticals, INC. | $58.76 | 2023 | Purified Cortrophin Gel |
| Celgene Corporation | $57.87 | 2022 | |
| Philips North America LLC | $52.55 | 2024-2025 | (Ck4) Mcot, Ecc Solutions |
| Genzyme Corporation | $35.40 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $22.41 | 2023 | Dysport |
| Astrazeneca Pharmaceuticals LP | $21.58 | 2025 | Wainua |
| Tg Therapeutics, INC. | $14.84 | 2023 | |
| Emd Serono, INC. | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anvi Gadani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.